Abstract
In the elusive quest for "personalized" cancer treatments based on pharmacogenomics, diverse challenges must be overcome: questionable validity of "molecular models of life," obstacles to bidirectional translation of scientific advances from bench to bedside to community, and limitations of bioinformatics to recognize and deal with "ignoramics/ignoromes" (expanding unknowns in cancer biology, theranostics, and therapeutic choices). These considerations apply to lymphatic system functioning-lymphatic vessels, lymph, lymph nodes, and lymphocytes-in diseases like cancer.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 501-507 |
| Number of pages | 7 |
| Journal | Journal of Surgical Oncology |
| Volume | 103 |
| Issue number | 6 |
| DOIs | |
| State | Published - May 1 2011 |
Keywords
- ignoramics
- lymphology
- personalized medicine
- pharmacogenomics
- surgicogenomics
- translation
ASJC Scopus subject areas
- Surgery
- Oncology